Our team is committed to developing new medicines to treat life-altering central nervous system (CNS) disorders. We are focused on advancing novel therapies through our understanding of the disease biology and translational findings. Our trials serve carefully selected patient populations who have limited treatment options.
A Phase 3 trial evaluating an oral therapeutic candidate in the treatment of postpartum depression (PPD).
This research study is evaluating the efficacy and safety of an investigational oral medication in women with PPD. An investigational medication is a study drug that will be tested during a study to see if it is safe and effective for a specific condition and/or group of people.
For more information about this trial and participating locations, visit the Robin Study website.
We are committed to respecting the primary role of healthcare providers in the treatment of CNS disorders. Therefore, we cannot respond to medical questions about your personal health situation, nor can we accept private medical information. Please contact your healthcare provider with any questions pertaining to your or a family member’s medical condition.
Sage is committed to discovering, developing and commercializing novel medicines to transform the lives of patients with life-altering central nervous system disorders. As part of this mission, we conduct clinical trials to determine if our investigational medicines are safe and effective for patients with a particular disease, disorder or condition which may allow us to seek the necessary regulatory approvals to provide wide access to these medicines.
We understand that, in some cases, patients with serious diseases or conditions may not be eligible for clinical trials and may not have other treatment options. Under very limited circumstances, we will consider making investigational medicines available for individual patients to treat a serious disease or condition outside of a clinical trial. This type of access is often referred to as “expanded access” or “compassionate use”. The following criteria must typically be met before we will consider making one of our investigational medicines available to individuals under an expanded access program:
Treating physicians should submit expanded access requests on behalf of patients to Sage at sagerx.com/contact-us. Please do not include a patient’s personally identifiable information in any request. Requests are assessed, on a case-by-case basis, by a team at Sage that includes medical professionals who are familiar with the data collected on the investigational medicine. In evaluating a request for expanded access, we may consider all relevant factors not just those specified above, including other factors relevant to patient safety. We anticipate acknowledging receipt of requests within five business days. If required, the regulatory agency in the relevant country must also approve the proposed use of the investigational medicine. The requesting physician must agree to obtain appropriate regulatory and ethics committee approvals, if applicable, and to comply with all other safety, monitoring, and patient consent requirements.
If a request is granted, expanded access will be discontinued as soon as feasible when approval of the drug is achieved in the country, subject to any legal or regulatory requirements.
Additional information regarding our clinical studies can be found at clinicaltrials.gov.
In some cases, we may set up a program designed to provide access to a number of patients. We plan to fulfill applicable obligations to include information related to our expanded access activities on clinicaltrials.gov or other applicable registries.
We may revise this policy at any time consistent with applicable law and regulations.